These findings suggested a novel therapeutic strategy that sequences chemotherapy with CDK4/6 inhibition to enhance the efficacy of chemotherapy followed by CDK4/6 inhibitor maintenance to delay recurrence of ovarian cancer (26). The gene discussed is CDK4; the disease is ovarian carcinoma.